Morepen Laboratories Dividend 2026 | ₹0.20/Share — Record Date, Ex-Date, Yield Analysis

Morepen Laboratories Limited (NSE: MOREPENLAB | BSE: 500288 | ISIN: INE083A01026) is a Gurugram-headquartered pharmaceutical company engaged in API manufacturing, formulations, home diagnostics, and medical devices. Founded in 1984, the company operates manufacturing facilities in Baddi (Himachal Pradesh) and has expanded into CDMO (Contract Development and Manufacturing Organisation) services. Its consumer brands include Dr. Morepen (glucometers, BP monitors, thermometers) and Burnol. The company is currently hiving off its Medical Devices business to subsidiary Morepen Medipath Limited via a Business Transfer Agreement at a slump sale consideration of ₹197.10 Crore. With a market capitalisation of approximately ₹6,604 Crore and promoter holding of 28.63%, Morepen has 54.79 Crore equity shares outstanding on a face value of ₹2 each.

Morepen’s decision to maintain the ₹0.20 dividend despite a 19.6% decline in consolidated PAT and deeply negative free cash flow signals management’s intent to establish a dividend track record. However, the dividend is largely symbolic — at ₹10.96 Crore, it represents just 11.55% of consolidated PAT. The real story is the aggressive capex programme: ₹160.54 Crore invested in PPE and intangibles against only ₹32.64 Crore operating cash flow. This expansion is being financed through a 145% surge in borrowings (₹79.39 Cr to ₹194.69 Cr). The company is simultaneously executing a medical devices business hive-off to Morepen Medipath at ₹197.10 Crore, a subsidiary exit (Dr. Morepen), and a CDMO capacity expansion — a complex multi-front transformation that demands careful monitoring.

Morepen’s future dividend trajectory hinges on whether its heavy capex translates into revenue and margin expansion. The CDMO pivot positions it in a high-growth pharmaceutical outsourcing segment, but returns are typically delayed by 2–3 years post capacity commissioning. Near-term earnings face headwinds from elevated depreciation on new assets, higher finance costs from the borrowing surge, and potential one-time costs related to the medical devices business transfer. The Q1 FY27 PAT recovery (+425% QoQ per market reports) provides some reassurance, though base effects contributed significantly. Dividend growth beyond ₹0.20 appears unlikely until FCF turns positive, which requires operating cash flow to materially outpace capex — a development unlikely before FY28 at the earliest.

The Board of Directors of Morepen Laboratories Limited, at their meeting held on 26th May, 2026 (3:00 PM – 5:15 PM), recommended a final dividend of ₹0.20 per equity share (10% on face value of ₹2 each) for the financial year ended 31st March, 2026. The dividend was subject to approval by members at the Annual General Meeting, which was held on 26th September, 2026. Per Note 3 of the filing, the Board has the right to decrease but not increase the recommended amount. No dividend is payable on 50,62,872 shares surrendered and cancelled by NCLT order (pending formal cancellation by stock exchanges).

Morepen Laboratories has an extremely limited dividend history. The company was incorporated in 1984 and paid no dividends for approximately four decades. The first-ever dividend of ₹0.20 per share was declared for FY2024-25, followed by an identical ₹0.20 for FY2025-26. While back-to-back dividends are encouraging, two data points do not establish a pattern. The flat ₹0.20 level despite 172% stock price appreciation suggests the company prioritises capital reinvestment over shareholder distributions — consistent with its heavy capex phase. The cash flow statement confirms dividend paid of ₹10.86 Crore in FY26 (representing the FY25 dividend), proving actual cash disbursement. No special or interim dividends have ever been declared.

Morepen’s 0.17% yield is among the lowest in the API/pharma peer group. Its ROE of 7.90% and ROCE of 8.29% are below peer averages, reflecting the ongoing capex cycle’s drag on returns. The low debt-to-equity (0.16x) is a positive but is deteriorating rapidly. Among peers, Divi’s Labs offers significantly superior dividend yield, profitability, and debt metrics.

With a 28.63% stake, promoters receive ₹3.14 Crore from the ₹10.96 Crore dividend outflow. The remaining ₹7.82 Crore goes to public and institutional shareholders. The relatively modest promoter holding (below the 50%+ typical of family-run pharma companies) means promoters have limited direct financial incentive from dividends. The dividend at ₹0.20/share appears to be driven more by signalling intent to establish a track record rather than channelling cash to promoters. FII holding stands at approximately 1.31% and DII holding at approximately 2.73%, with retail dominating the non-promoter base.

Under current Indian tax law, dividends are taxable in the hands of shareholders at their applicable income tax slab rate. TDS at 10% is deducted on dividend exceeding ₹5,000 in a financial year from a single company. For NRIs, TDS is deducted at 20% (plus applicable surcharge and cess).

Worked Example: 1,000 Shares | 30% Tax Slab

At the 30% tax slab, the already minimal 0.17% pre-tax yield compresses to an effective yield of just 0.11%.

• 1. Negative Free Cash Flow: FCF of ₹–127.90 Cr means the company cannot fund dividends, capex, and operations from internal accruals. The capex cycle (₹160.54 Cr in FY26) is being financed through debt, creating future repayment obligations.
• 2. Borrowing Surge: Total borrowings tripled from ₹79.39 Cr to ₹194.69 Cr in one year. If CDMO capacity ramp-up is delayed or yields lower-than-expected returns, this debt could become burdensome.
• 3. Earnings Quality Deterioration: FY26 PAT includes a ₹25.83 Cr exceptional gain. Core earnings (ex-exceptional) declined approximately 40% YoY. Operating cash flow was only 34% of reported PAT, indicating poor earnings quality.
• 4. Business Restructuring Execution Risk: Simultaneous Medical Devices hive-off (BTA with Morepen Medipath at ₹197.10 Cr), Dr. Morepen subsidiary exit, and CDMO expansion create execution complexity. Delays or cost overruns could impair near-term performance.
• 5. Receivables and Working Capital Stress: Trade receivables of ₹333.14 Cr (67 days of sales) grew despite flat revenue, absorbing ₹50.12 Cr of cash. If collection efficiency worsens further, working capital needs could consume any remaining operating cash flow.
• 6. Customer and Revenue Concentration: API manufacturing and CDMO services face concentration risk if a few clients account for a large revenue share. Loss of key contracts could significantly impact results.
• 7. Regulatory and Compliance Risk: Pharma manufacturing is subject to USFDA, WHO-GMP, and other regulatory inspections. Any adverse regulatory action at manufacturing facilities could disrupt operations and revenue.

• 1. FCF Inflection Point: Track quarterly OCF vs capex trajectory. FCF turning positive would be the single strongest signal that dividend growth can follow.
• 2. CDMO Revenue Ramp: Monitor new CDMO contract announcements, reactor utilisation rates, and revenue contribution from CDMO segment in quarterly results.
• 3. Debt Trajectory: Watch whether borrowings stabilise or continue rising. A borrowing-to-equity ratio crossing 0.30x would warrant heightened concern.
• 4. Receivables Quality: Track debtor days and provisioning for doubtful debts. A further increase in receivables without corresponding revenue growth is a red flag.
• 5. Medical Devices Transfer Completion: Monitor completion of the BTA with Morepen Medipath and receipt of the ₹197.10 Cr consideration, which could materially improve the cash position.
• 6. Margin Recovery: Track EBITDA margin trends — currently compressed by rising employee costs, distribution expenses, and finance costs.
• 7. Q2-Q4 FY27 Earnings Consistency: The Q1 FY27 recovery (+425% QoQ) needs to sustain over subsequent quarters to confirm it is not a one-off base effect.

Morepen Laboratories’ ₹0.20 final dividend for FY2025-26 is a symbolic gesture rather than a meaningful income distribution. At a yield of just 0.17%, income-focused investors will find little value here. The company is in the midst of an ambitious transformation — pivoting to CDMO, hiving off its medical devices business, and exiting non-core subsidiaries — all financed by a 145% surge in borrowings. Core earnings (excluding a ₹25.83 Cr exceptional gain) declined approximately 40%, and free cash flow remains deeply negative at ₹–127.90 Crore. The dividend’s sustainability at ₹0.20 is intact given the modest outflow of ₹10.96 Crore, but growth in dividends is improbable until the capex cycle matures. This is a stock to evaluate for its CDMO growth potential, not for dividend income.